Methadone
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Methadone: From Opioid Use Disorder to Tourette Syndrome
One-Sentence Summary
Methadone is a long-acting synthetic opioid, established in clinical practice as opioid agonist maintenance therapy for opioid use disorder and as an analgesic for chronic/cancer pain. The TxGNN model predicts it may be effective for Tourette Syndrome, but this direction is currently supported by only 1 case report and a handful of indirect, mechanism-adjacent publications — no clinical trials have been registered for this indication.
Note: The evidence pack contains no original_indications or license data for this drug; the original indication above reflects general pharmacological knowledge of methadone, not structured evidence-pack data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Opioid use disorder (maintenance therapy) / chronic pain management (not captured in evidence pack; based on general drug knowledge) |
| Predicted New Indication | Tourette Syndrome |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L4 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for methadone is not available in this evidence pack. Based on general pharmacological knowledge, methadone is a synthetic opioid that acts as a full mu-opioid receptor agonist and also antagonizes NMDA receptors and inhibits monoamine reuptake — a pharmacological profile distinct from typical short-acting opioids.
The link to Tourette syndrome is not mechanistically established. The rationale rests almost entirely on a single 1992 case report describing methadone treatment of Tourette’s disorder, alongside indirect literature discussing opioid-system involvement in chorea, tic disorders, and obsessive-compulsive symptoms. These publications suggest a theoretical role for opioidergic modulation in hyperkinetic/tic-related movement disorders, but none provide a direct mechanistic pathway or controlled clinical evidence connecting methadone specifically to tic suppression.
Given the absence of clinical trials, an unconfirmed mechanistic rationale, and reliance on a single decades-old case report, this prediction should be treated as hypothesis-generating rather than clinically actionable at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15247538 | 2004 | Review | Current Opinion in Neurology | Reviews non-genetic causes of chorea; notes growing interest in whether Sydenham’s chorea mechanisms play a role in other neuropsychiatric disorders |
| 39086469 | 2024 | Review | Palliative Care and Social Practice | Reviews novel-mechanism analgesics for neuropathic pain in advanced illness (haloperidol, miragabalin, PEA, clonidine); not methadone-specific |
| 1728167 | 1992 | Case report | The American Journal of Psychiatry | Direct case report of methadone used to treat Tourette’s disorder — the only direct clinical evidence in this evidence pack |
| 30395551 | 2018 | Case series | Journal of Psychiatric Practice | Describes heroin addiction comorbidity in Serbian patients with Tourette syndrome; addresses TS-addiction association, not methadone efficacy for TS |
| 17102981 | 2007 | Basic/experimental | Psychopharmacology | Experimental study of atypical opiates and 5-HT2A/C receptor-mediated behavior relevant to OCD/tic-like symptoms; preclinical, not methadone-specific |
US Market Information
No license or NDA records were found for methadone in this evidence pack (total_licenses: 0, market status: Not Marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The only direct clinical evidence for methadone in Tourette syndrome is a single 1992 case report, with no registered clinical trials and no confirmed mechanistic pathway. Evidence level is L4 (preclinical/mechanism-adjacent only), which does not support advancing past initial hold at this stage.
To proceed, the following is needed:
- TFDA/FDA label warnings and contraindications (currently a Blocking data gap — required before any S1 safety evaluation)
- Confirmed mechanism of action data for methadone
- Confirmed original indication and regulatory license data (currently absent from the evidence pack)
- Additional controlled clinical evidence (case series, cohort study, or trial) beyond the single 1992 case report before considering escalation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.